Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey
-
By
-
Eric Boodman
-
March 23, 2026
-
Clinical Scorecard: A Challenging Path to Fecal Transplantation for a Severe C. difficile Infection in Her Son
At a Glance
| Category | Detail |
| Condition | Clostridioides difficile infection (CDI) |
| Key Mechanisms | Disruption of gut microbiota leading to C. difficile overgrowth and toxin production. |
| Target Population | Pediatric patients, particularly those with recurrent CDI. |
| Care Setting | Hospital and outpatient settings. |
Key Highlights
- Fecal microbiota transplant (FMT) aims to restore gut microbiota diversity.
- FDA halted shipments from major stool bank, limiting treatment options.
- New FDA-approved drugs for CDI are not suitable for children or severe cases.
- FMT has shown high success rates compared to traditional antibiotics.
- Cost of new treatments can be prohibitively expensive.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of CDI is based on clinical symptoms and laboratory testing for toxins.
Management
- Consider FMT for patients with recurrent CDI after standard antibiotic treatments fail.
Monitoring & Follow-up
- Monitor for recurrence of CDI after treatment.
Risks
- Potential risks include transmission of infectious agents and adverse reactions.
Patient & Prescribing Data
Children with recurrent CDI, particularly those unresponsive to antibiotics.
FMT is a viable alternative when conventional therapies fail.
Clinical Best Practices
- Ensure thorough screening of stool donors to minimize infection risk.
- Educate families about the benefits and risks of FMT.
Related Resources & Content